(LTRN) – Management Comments
-
Lantern Pharma (LTRN) Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
-
Lantern Pharma (LTRN) Tops Q1 EPS by 3c
-
-
-
Back to LTRN Stock Lookup